AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Licensing deal signed with Gilead Sciences for smallpox drug.
2003 OCT 8 - (NewsRx.com & NewsRx.net) -- Chimerix, Inc., an emerging biotechnology company developing orally available, targeted medicines from bioactive molecules, announced that it has licensed rights from Gilead Sciences, Inc., (GILD) to develop oral derivatives of Gilead's proprietary antiviral compound cidofovir, intended for the prevention or treatment of smallpox infections.
Chimerix's initial focus will be to continue the development of its oral smallpox drug, CMX-001, which is a chemically modified derivative of cidofovir, derived by incorporating Chimerix proprietary chemistry to enhance intracellular uptake and oral delivery.
The license permits Chimerix to sell CMX-001 to governments anywhere in the world. The license also includes the rights to develop and sell oral derivatives of cidofovir for treatment of infections caused by related viruses such as vaccinia virus (the virus used for smallpox vaccinations) and monkeypox virus (a smallpox-related virus found in animals, which can be passed on to humans). Chimerix will pay Gilead royalties based on a percentage of net sales to governments. Specific terms of the agreement were not disclosed.
Cidofovir is an antiviral medication currently approved for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients. Marketed under the brand name Vistide, Gilead's drug was cleared for marketing by the U.S. Food and Drug Administration in 1996 and by European regulators in 1997. Cidofovir is administered by intravenous infusion.
Using ...
- Chimerix Raises $11 Million in Series C Financing to Advance Smallpox Drug and...
- Press release article from: PR Newswire November 4, 2004 700+ words
...SAN DIEGO, Nov. 4 /PRNewswire/ -- Chimerix Inc., an emerging biotechnology company...Frazier Healthcare Ventures, will join Chimerix's board of directors. Additional funding...Painter, Ph.D., president and CEO of Chimerix, Inc. "The funds will allow Chimerix...
- Chimerix Raises $23.1 Million to Advance Antiviral Drug Pipeline.
- Press release article from: PR Newswire February 23, 2007 700+ words
...N.C., Feb. 23 /PRNewswire/ -- Chimerix Inc., a biotechnology company developing...partner with Canaan Partners, will join Chimerix's board of directors. Additional funding...expertise that both Seth and Ed bring to Chimerix's board will be invaluable as the company...
- Chimerix Awarded $36.1M NIH Grant to Develop Its Oral Drug for the Treatment of...
- Press release article from: PR Newswire September 9, 2003 700+ words
...SAN DIEGO, Sept. 9 /PRNewswire/ -- Chimerix Inc., an emerging biotechnology company...The grant will fund the development of Chimerix's oral antiviral drug for the treatment...Modification of cidofovir using proprietary Chimerix chemistry yields a new drug, CMX-001...
- Chimerix Awarded NIH Grant to Fund Drug Development for Multi-Drug Resistant...
- Press release article from: PR Newswire March 11, 2004 700+ words
...SAN DIEGO, March 11 /PRNewswire/ -- Chimerix Inc., a biotechnology company developing...potential to succeed as commercial products. Chimerix will use the two year, $600,000 grant...Painter, Ph.D., President and CEO of Chimerix. "New classes of anti-retroviral...
- Chimerix, Inc. Announces Selection as a Top 5 Nominee for 2005 World Technology...
- Press release article from: PR Newswire November 10, 2005 700+ words
Chimerix Named Corporate Member in the World Technology...N.C., Nov. 10 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing...global marketplace impact. In addition, Chimerix was named a WTN corporate member, a peer...
- Chimerix Acquires Lead Compound Library of Antiviral Agents From University of...
- Press release article from: PR Newswire May 24, 2006 700+ words
...N.C., May 24 /PRNewswire/ -- Chimerix, Inc., an emerging biotechnology company...key antiviral and oncology targets. Chimerix will incorporate promising candidates...into targeted tissues. Additionally, Chimerix intends to license out promising oncology...
- Chimerix Announces Initiation of Phase I Clinical Trials of CMX001, an Oral...
- Press release article from: PR Newswire June 28, 2006 700+ words
...N.C., June 28 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing...systems," said Dr. George Painter, Chimerix President and CEO. "Using our platform...associated with smallpox vaccination." Chimerix will initiate a single-site Phase I...
- Chimerix, Inc. Announces Appointment of Expert In Antiviral Discovery and...
- Press release article from: PR Newswire October 9, 2002 700+ words
SAN DIEGO -- Chimerix, Inc., an emerging biotechnology...of the founding management team. "Chimerix has the potential to address unmet medical...Modifying bioactive molecules using Chimerix chemistry can improve oral bioavailability...
- Chimerix Granted Patent for CMX001, an Orally-Active Smallpox Therapeutic.
- Press release article from: PR Newswire April 27, 2004 700+ words
...SAN DIEGO, April 27 /PRNewswire/ -- Chimerix Inc. and the University of California...granted world-wide exclusive rights to Chimerix for commercialization of the modified...phosphonate compounds described in the patent. Chimerix is currently developing CMX001, an orally...
- Merial to Screen Chimerix' Chemical Library for Animal Health Drug Leads.
- Press release article from: PR Newswire January 29, 2008 700+ words
...PRNewswire/ -- Merial Limited and Chimerix, Inc. announced today that they have...agreement under which Merial will screen a Chimerix chemical library for animal health drug...an option to negotiate a license with Chimerix for leads identified for possible animal...
Source: HighBeam Research, Licensing deal signed with Gilead Sciences for smallpox drug.